Bio Pharma Dive

APRIL 19, 2021

Adagio Therapeutics, a well-financed spinout of antibody developer Adimab, could challenge Regeneron and Eli Lilly if its drug candidate proves protective in clinical tests.

Antibody 335

Antibody Drugs Development 335

Bio Pharma Dive

NOVEMBER 5, 2020

Fast antibody testing, however, is spotty. The drug, now being considered for emergency clearance by the FDA, seems to work best in patients whose immune systems haven't responded to infection.

Antibody 300

Antibody Drugs 300

Bio Pharma Dive

MAY 24, 2021

Pharma and biotech companies alike see potential in using bispecific antibodies for hard-to-treat cancers like leukemia, myeloma and solid tumors.

Antibody 312

Antibody Drugs 312

Bio Pharma Dive

SEPTEMBER 14, 2020

Merck's deal for Seattle Genetics' antibody-drug conjugate comes as Gilead agreed to acquire rival developer Immunomedics in the biotech industry's largest buyout of 2020.

Genetics 300

Genetics Antibody Drugs Development 300

Pharmaceutical Technology

APRIL 21, 2023

Twist Bioscience and Astellas Pharma have entered a collaboration to help the latter to discover antibodies for immunotherapies. In May 2022, they signed a research partnership and exclusive option licence agreement for the development of antibodies to reduce tumour microenvironment-mediated immunosuppression.

Antibody 264

Antibody Licensing Licensing Protein 264

Bio Pharma Dive

JANUARY 12, 2021

Moderna and Gilead reported billions in sales for their coronavirus treatments, but Regeneron's antibody drug cocktail hasn't gained traction. BioNTech, meanwhile, could report critical new vaccine results in days.

Antibody 298

Antibody Vaccine Vaccination Drugs 298

Bio Pharma Dive

DECEMBER 8, 2020

But a growing group of antibody drugs, several of which were showcased at ASH, aren't far behind. Two cell therapies might soon be approved for the blood cancer.

Antibody 294

Antibody Drugs 294

Pharmaceutical Technology

MARCH 16, 2023

Talem Therapeutics, a subsidiary of Immunoprecise Antibodies, has entered a multi-target artificial intelligence (AI)-driven antibody discovery collaboration with Libera Bio. The MPN Technology provides an elegant way for delivering antibodies inside tumour cells.

Antibody 262

Antibody In-Vivo Pharma Companies Protein 262

Bio Pharma Dive

OCTOBER 8, 2020

The two antibody treatments are now being reviewed by the FDA, although limited supply could mean their impact won't be felt for months, even if they are cleared for use.

Antibody 300

Antibody Drugs 300

Bio Pharma Dive

JULY 28, 2021

The acquisition is the third Amgen has made since March and broadens its ability to develop bispecific antibodies, a drug class of intense interest to big biotech.

Antibody 294

Antibody Drugs Development 294

Pharmaceutical Technology

JULY 21, 2022

AstraZeneca has signed a deal with the Federal Office of Public Health (FOPH) of Switzerland to deliver over 1,200 doses of antibody therapy, tixagevimab and cilgavimab combination (AZD7442), for Covid-19 prevention and treatment. In June 2020, these antibodies, discovered at Vanderbilt University Medical Center, were licensed to AstraZeneca.

Antibody 264

Antibody Compliance Clinical Trials Clinical Trials 264

Pharmaceutical Technology

FEBRUARY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology: Leading companies in cancer monoclonal antibody therapy. Immatics is one of the most important players concerning innovation surrounding cancer monoclonal antibody therapy.

Antibody 261

Antibody Immune Response Protein Development 261

Pharmaceutical Technology

AUGUST 24, 2023

Japan has granted a new drug substance patent for BioArctic’s monoclonal antibody (mAb), BAN0805, to treat Parkinson’s disease.

Antibody 245

Antibody Drugs 245

Pharmaceutical Technology

FEBRUARY 19, 2024

Almirall has signed a licensing agreement for the acquisition of worldwide rights to Novo Nordisk’s IL21-hindering antibody NN-8828.

Licensing 241

Licensing Licensing Antibody 241

Pharmaceutical Technology

JULY 4, 2022

Brii Biosciences (Brii Bio) has exercised an option for the acquisition of exclusive development and marketing rights for Vir Biotechnology’s investigational antibody, VIR-3434, for Hepatitis B in Greater China, under a partnership agreement. The mAb is presently in the Phase II development stage.

Antibody 279

Antibody Genotype Development Licensing 279

Bio Pharma Dive

FEBRUARY 11, 2022

Distribution of Lilly's earlier antibody treatments was halted as testing showed them ineffective against omicron. Bebtelovimab appears able to neutralize the variant, and was authorized by the FDA on Friday.

Antibody 268

Antibody 268

Pharmaceutical Technology

JANUARY 9, 2023

Eisai and Biogen have received approval for their antibody Leqembi (lecanemab-irmb) , 100mg/mL injection for intravenous use, from the US Food and Drug Administration (FDA) under the Accelerated Approval Pathway to treat Alzheimer’s disease (AD). The regulatory approval is based on the data obtained from the Phase II trial.

FDA Approval 246

FDA Approval Antibody Clinical Trials Clinical Trials 246

Pharmaceutical Technology

OCTOBER 21, 2022

AbbVie has announced the acquisition of UK-based biotechnology firm DJS Antibodies for nearly $255m in cash at closing. DJS focuses on the discovery and development of antibody therapies that act on difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs).

Antibody 217

Antibody Protein Licensing Licensing 217

Pharmaceutical Technology

MAY 8, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Anti-influenza antibody compositions. However, not all innovations are equal and nor do they follow a constant upward trend.

Antibody 246

Antibody Vaccination Vaccine Dermatology 246

Bio Pharma Dive

DECEMBER 23, 2021

The decision follows worrisome results in lab studies that indicated omicron can evade both drugs and leaves the U.S. with fewer treatments to respond to the variant's spread.

Antibody 345

Antibody Drugs 345

Pharmaceutical Technology

FEBRUARY 27, 2025

IPA has entered a strategic partnership with Ribopro aiming to transform therapeutic antibody discovery and development.

Antibody 147

Antibody Development 147

Bio Pharma Dive

JULY 27, 2022

The companies pitch their collaboration as a way to give young drugmakers backed by Versant a head start. “Our business is advanced by great ideas coming into the funnel,” said AbCellera’s CEO.

Antibody 331

Antibody 331

Bio Pharma Dive

MAY 25, 2023

Study abstracts released Thursday give investors and analysts a better look at cancer treatments recently licensed by Merck and BioNTech as well as fresh details on other closely watched ADC candidates.

Antibody 316

Antibody Licensing Licensing Drugs 316

Medical Xpress

JANUARY 17, 2025

Ideally, the immune system will produce long-lasting antibodies recognizing that specific virus, thereby providing protection. Many vaccines work by introducing a protein to the body that resembles part of a virus.

Antibody 144

Antibody Vaccine Vaccination Protein 144

Bio Pharma Dive

MAY 7, 2024

The $200 million round is the latest evidence that surging interest in autoimmune disease cell therapies could expand to include developers of bispecific antibodies, too.

Antibody 177

Antibody Development 177

Bio Pharma Dive

AUGUST 3, 2020

Seeking fast answers in a pandemic, Lilly will use mobile RVs to set up infusion clinics at assisted living facilities, which have become COVID-19 hot spots.

Nurses 340

Nurses Antibody Drugs 340

Pharmaceutical Technology

FEBRUARY 13, 2025

AbbVie has entered a partnership and option-to-license agreement with Xilio for tumour-activated, antibody-based immunotherapies.

Antibody 162

Antibody Licensing Licensing 162

Bio Pharma Dive

APRIL 16, 2021

The request comes less than six months after the FDA authorized Lilly's bamlanivimab, reflecting the spread of virus variants that can elude the drug.

Antibody 337

Antibody Drugs 337

Bio Pharma Dive

OCTOBER 7, 2020

The pharma is the first to seek emergency approval for this kind of treatment, and may quickly follow up with a second request after reporting promising data for a two-drug combination.

Antibody 334

Antibody Drugs 334

Bio Pharma Dive

OCTOBER 18, 2024

Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval by the 2025-2026 season.

Antibody 269

Antibody Trials 269

Pharmaceutical Technology

FEBRUARY 17, 2025

Two of Bambusas bispecific antibody candidates for immunological and inflammatory disorders are set to enter the clinic in 2025.

Antibody 162

Antibody Clinical Trials Clinical Trials Trials 162

Bio Pharma Dive

AUGUST 9, 2024

The deal hands Merck a cancer medicine already in human testing, but that the company sees as a potential treatment for autoimmune conditions, too.

Antibody 286

Antibody Medicine 286

Bio Pharma Dive

APRIL 3, 2024

The startup claims to have a more efficient way to develop biologic drugs that treat disease by turning on cellular pathways, rather than blocking them.

Antibody 286

Antibody Drugs Development 286

Bio Pharma Dive

SEPTEMBER 6, 2024

New trial results could offer support for an expansion of Nucala’s label after U.S. regulators rejected GSK’s submission in 2018.

Trials 253

Trials Antibody Regulation Drugs 253

Bio Pharma Dive

JANUARY 26, 2021

The results show that drugs from both companies can help prevent or treat COVID-19 when given at the right time. But that won't mean much if barriers to use remain high.

Antibody 334

Antibody Drugs 334

Pharmaceutical Technology

MARCH 7, 2024

Gilead Sciences has entered an agreement with Merus for the discovery of dual tumour-associated antigens targeting trispecific antibodies.

Antibody 162

Antibody 162

Bio Pharma Dive

FEBRUARY 10, 2025

Antibody-drug conjugates (ADCs) are revolutionizing oncology, but success requires precision diagnostics.

Antibody 147

Antibody Drugs 147